NL-OMON46944已完成不适用
AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY THAT TARGETS THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS - BP29541 / CEA TCB
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* For dose escalation, locally advanced and/or metastatic gastrointestinal solid tumor in patients who have progressed on a standard therapy, are intolerant to SOC, and/or are non-amenable to SOC and other solid tumors expressing CEA as per inclusion criterion 14.
- •* Radiologically measurable disease according to RECIST v1.1
- •* Life expectancy (in the opinion of the investigator) of ><= 12 weeks and lactate dehydrogenase levels <<= 2.5 upper limit of normal
- •* Eastern Cooperative Oncology Group Performance Status (PS) 0-1
- •* All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade <<= 1 or returned to
- •baseline except alopecia (any grade) and Grade 2 peripheral neuropathy
- •* Adequate hematological, liver and renal function
- •* Patients must agree to be willing to use effective methods of contraception as defined in the protocol
- •* Non-gastrointestinal solid tumors (like non-small cell lung cancer or breast cancer patients) should have confirmed CEA expression in tumor tissue ><= 20% of tumor cells staining with at least moderate to high intensity of CEA expression are required (Immunohistochemistry [IHC] 2+ and IHC3+). For CRC patients only, the CEA assessment should be performed but the result is not required to enroll the patient.
- •* For the biomarker cohort, only patients with moderate/low CEA expression and very low/negative CEA expression or IHCO+ will be enrolled. CEA expression should be determined prior to enrollment.
排除标准
- •1.Active or untreated central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments
- •2. Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for 2 weeks prior to enrollment.
- •3. Leptomeningeal disease.
- •4. patients with paraspinal, paratracheal and mediastinal pathological lesions larger than 2 cm inless they are previously irridiated.
- •5. Patients with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the investigator to be of low likelihood for recurrence)
- •6. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or contraindicate the use of an investigational drug, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases
- •7. Patients with bilateral lung lesions and dyspnea and/or with bilateral lung lesions and SaO2 < 92% (at rest, room air) or patients with lobectomy or pneumonectomy with lung metastases in the remaining lung and either dyspnea or SaO2 less than 92% (at rest, room air) at baseline
研究者
相似试验
已完成
不适用
AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1) IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORSGevorderde en/of gemetastaseerde solide tumorenadvanced and/or metastatic solid tumorsCancerNL-OMON44807Roche Nederland B.V.30
已完成
不适用
AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONISTIC MONOCLONAL ANTIBODY) OR BEVACIZUMAB (ANTI-VEGF MONOCLONAL ANTIBODY, PART II) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY) IN PATIENTS WITH METASTATIC SOLID TUMORSCancerNL-OMON47188Roche Nederland B.V.20
进行中（未招募）
1 期
A Study of RO7009789 in Combination with MPDL3280A in Patients with Locally Advanced and Metastatic Solid Tumorsocally Advanced and/ or Metastatic Solid TumorsMedDRA version: 17.0 Level: LLT Classification code 10065143 Term: Malignant solid tumour System Organ Class: 100000004864EUCTR2014-002835-32-ESRoche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd135
进行中（未招募）
1 期
A Study of RO7009789 in Combination with MPDL3280A in Patients with Locally Advanced and Metastatic Solid Tumorsocally Advanced and/ or Metastatic Solid TumorsMedDRA version: 20.1 Level: LLT Classification code 10065143 Term: Malignant solid tumour System Organ Class: 100000004864EUCTR2014-002835-32-FRF. Hoffmann-La Roche Ltd135
已完成
不适用
AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE CONSISTING OF INTERLEUKIN 2 VARIANT (IL-2v) TARGETING FIBROBLAST ACTIVATION PROTEIN-* (FAP), AS A SINGLE AGENT (PART A) OR IN COMBINATION WITH TRASTUZUMAB OR CETUXIMABsolide tumoren ( part A), Borstkanker (part B), (plaveiselcarcinoom hoofd/hals (partC)solid tumorsCancerNL-OMON46970Roche Nederland B.V.20